溃疡性结肠炎患者升级至抗代谢药治疗后继续与停用5-氨基水杨酸均无获益
本研究利用去标识化行政索赔数据库,比较溃疡性结肠炎(UC)患者升级至抗代谢药单药治疗后继续与停用5-氨基水杨酸(5-ASA)的模式和结局。在4068例UC患者中,持续使用5-ASA与UC相关住院(HR 1.40 [1.07-1.83])和皮质类固醇使用(HR 1.48 [1.28-1.70])风险升高相关,而UC相关手术(HR 1.32 [0.86-2.00])或治疗升级(HR 0.80 [0.53-1.20])风险未增加。结论认为5-ASA在升级至抗代谢药治疗后通常长期继续使用,但无临床获益。
要点
- 在升级至抗代谢药单药治疗的UC患者中,66.6%持续使用5-ASA超过6个月。
- 与停用5-ASA相比,持续使用5-ASA与UC相关住院风险升高相关(HR 1.40 [1.07-1.83])。
- 持续使用5-ASA与皮质类固醇使用风险升高相关(HR 1.48 [1.28-1.70]),手术和治疗升级风险未显著增加。
核心结论
- 在UC患者升级至抗代谢药治疗后,继续使用5-ASA无临床获益,但仍常被长期继续使用。
研究设计与样本
- 利用去标识化行政索赔数据库的队列研究,纳入4068例新开始抗代谢药单药治疗且正在使用5-ASA的UC患者,随访至少12个月。
主要发现
- 4068例UC患者中,578例(14.2%)停用5-ASA,782例(19.2%)短期使用5-ASA(开始抗代谢药后<6个月),2708例(66.6%)持续使用5-ASA(开始抗代谢药后>6个月)。
- 与停用5-ASA相比,持续使用5-ASA与UC相关住院风险升高相关(HR 1.40 [1.07-1.83])。
- 与停用5-ASA相比,持续使用5-ASA与皮质类固醇使用风险升高相关(HR 1.48 [1.28-1.70])。
- 与停用5-ASA相比,持续使用5-ASA与UC相关手术风险(HR 1.32 [0.86-2.00])和治疗升级风险(HR 0.80 [0.53-1.20])无显著增加相关。
- 使用开始抗代谢药后3个月窗口分类继续与停用5-ASA的敏感性分析显示类似结果。
局限性
- 不能排除疾病严重程度所致的残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whilst continuation of 5-aminosalicylates (5-ASA) after escalation to biologic therapy is considered ineffective in patients with ulcerative colitis (UC), their role in patients escalated to anti-metabolites is unclear. AIM: To compared patterns and outcomes of continuing vs stopping 5-ASA in patients with UC who escalated to anti-metabolite monotherapy, using a de-identified administrative claims database. METHODS: We identified patients with UC who were new users of anti-metabolite monotherapy who were receiving 5-ASA, and were followed for at least 12 months after starting anti-metabolite therapy. We evaluated patterns of 5-ASA use (stopped 5-ASA, short-term 5-ASA use for <6 months after starting anti-metabolites, persistent 5-ASA use for >6 months after starting anti-metabolites). We compared outcomes (risk of UC-related hospitalisation and/or surgery, need for corticosteroids, treatment escalation to biologic therapy) by pattern of 5-ASA use, using Cox proportional hazard analysis adjusting for age, sex, race, comorbidity burden, and hospitalisation or emergency department visit, abdominal surgery and corticosteroid use in the previous 12 months (as measures of disease severity), with a 12-month immortal time period. RESULTS: Of 4068 patients with UC who were new-users of anti-metabolite monotherapy, 578 (14.2%), 782 (19.2%) and 2708 (66.6%) stopped 5-ASA, used 5-ASA transiently or persistently, respectively. Compared to patients who stopped 5-ASA after starting anti-metabolites, persistent 5-ASA use was associated with a higher risk of UC-related hospitalisation (HR, 1.40 [1.07-1.83]) and corticosteroid use (HR, 1.48 [1.28-1.70]), without an increase in risk of UC-related surgery (HR, 1.32 [0.86-2.00]) or treatment escalation (HR, 0.80 [0.53-1.20]). Sensitivity analyses using a 3 months window after initiation of anti-metabolites to classify patients as continuing vs stopping 5-ASA showed similar results. Residual confounding by disease severity could not be excluded. CONCLUSION: 5-ASA are usually continued long-term even after escalating to anti-metabolite therapy in patients with UC without clinical benefit.
引用
- Singh S, Kim J, Zhu W, et al. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther. 2020. PMID: 32573825. doi:10.1111/apt.15876
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。